Anti-hypertensive effects -
This includes effective dosages that may be lower than those recommended by drug manufacturers. The PDR is the most used source of drug information among physicians, and it is heavily relied on by hospital staff who may lack the clinical experience to know that PDR dosage recommendations are general guidelines based on limited prerelease research, not on hard and fast rules of optimal therapeutics.
Moreover, although experts generally suggest reduced initial doses for older patients, the PDR does not recommend such reductions for old or even very old patients with 37 of 45 drugs.
If the JNC VI recommendations, which represent prerelease and postrelease data, are considered the state of the art, mechanisms need to be implemented by which these recommendations are incorporated into the PDR and the corresponding package inserts, where physicians are most likely to see and use them.
If such mechanisms cannot be established for the PDR , another source of current, readily available drug information should be created so that physicians' methods will keep pace with evolving standards of optimal pharmacotherapy for patients with hypertension.
Corresponding author: Jay S. Cohen, MD, Del Mar Heights Rd, , Del Mar, CA e-mail: jacohen uscd. full text icon Full Text. Download PDF Top of Article Abstract Compliance with antihypertensive treatment Adverse drug events and compliance Materials and methods Results Comment Conclusions Article Information References.
Table 1. View Large Download. Range of Dosages Provided by the Manufacturers of 45 Commonly Prescribed Antihypertensive Drugs. Not Available, The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
Luepker RVMcGovern PGSprafka JM et al. Unfavorable trends in the detection and treatment of hypertension: the Minnesota Heart Survey [abstract]. Meissner IWhisnant JPSheps S et al. Stroke prevention: assessment of risk in a community: the SPARC Study, I: blood pressure trends, treatment, and control [abstract].
Ann Neurol. Burt VLWhelton PRoccella EJ et al. Prevalence of hypertension in the US adult population: results from the third National Health and Nutrition Examination Survey, Burt VLCutler JAHiggins M et al.
Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, to Sanson-Fisher RWClover K Compliance in the treatment of hypertension: a need for action.
Am J Hypertens. Feldman RBacher MCampbell N et al. Adherence to pharmacologic management of hypertension. Can J Public Health. Alderman MHMadhavan SCohen H Antihypertensive drug therapy: the effect of JNC criteria on prescribing patterns and patient status through the first year.
Tomlinson B Optimal dosage of ACE inhibitors in older patients. Drugs Aging. Flack JMNovikov SVFerrario CM Benefits of adherence to anti-hypertensive drug therapy. Eur Heart J. Caro JJSalas MSpeckman JL et al.
Persistence with treatment for hypertension in actual practice. MacConnachie AMMaclean D Low dose combination antihypertensive therapy: additional efficacy without additional adverse effects? Drug Safety. Frick MHMcGibney DTyler HM Amlodipine: a double-blind evaluation of the dose-response relationship in mild to moderate hypertension.
J Cardiovasc Pharmacol. Flack JMYunis CPreisser J et al. ATIME Research Group, The rapidity of drug dose escalation influences blood pressure response and adverse effects burden in patients with hypertension: the Quinapril Titration Interval Management Evaluation ATIME Study.
Lip GYBeevers DG Doctors, nurses, pharmacists and patients: the Rational Evaluation and Choice in Hypertension REACH survey of hypertension care delivery. Blood Press. Not Available, Physicians' Desk Reference. Montvale, NJ Medical Economics Company;.
Montvale, NJ Medical Economics Co;. Cohen JSInsel PA The Physicians' Desk Reference : problems and possible improvements. Connelly DPRich ECCurley SPKelly JT Knowledge resource preferences of family physicians.
J Fam Pract. Ely JWBurch RJVinson DC The information needs of family physicians: case-specific clinical questions. Buckley B 34th Annual top drug issue. Pharmacy Times. April; 22 Google Scholar. American Society of Hospital Pharmacists, Hypotensive agents.
McEvoy GKed American Hospital Formulary Service Drug Information Bethesda, Md American Society of Hospital Pharmacists; Google Scholar. Sorrentino MJ Turning up the heat on hypertension: it's time to be more aggressive in finding and treating this silent killer.
Postgrad Med. Curzen NPurcell H Matching the treatment to the patient in hypertension. Elmer PJGrimm Jr RLaing B et al. Lifestyle intervention: results of the Treatment of Mild Hypertension Study TOMHS.
Prev Med. Liebson PRGrandits GADianzumba S et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study TOMHS.
Gran B Non-pharmacological methods reduce drug use in the treatment of hypertension: a two-year trial in general practice. Scand J Prim Health Care. Lazarou JPomeranz BHCorey PN Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.
Melmon KLMorrelli HFHoffman BBNierenberg DW Melmon and Morrelli's Clinical Pharmacology: Basic Principles in Therapeutics. New York, NY McGraw-Hill Co; Insinna FZarcone PCimino R Hypotensive drugs and first-dose syndrome: considerations on 6 cases observed during treatment with ACE inhibitors [in Italian].
Minerva Med. Mullen PJ Unexpected first dose hypotensive reaction to enalapril. Postgrad Med J. Montoliu JBotey ADarnell ARevert L Prolonged hypotension after the first dose of atenolol.
Med Clin Barc. Cushman WCBlack HR Hypertension in the elderly. Cardiol Clin. Monane MBohn RLGurwitz JH et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly.
Reynolds EBaron RB Hypertension in women and the elderly: some puzzling and some expected findings of treatment studies. Montamat SCCusack BJVestal RE Management of drug therapy in the elderly. N Engl J Med. Williams RD Medications and older adults. FDA Consumer. September-October; [Food and Drug Administration Web site].
Accessed December 8, Google Scholar. Brawn LACastleden CM Adverse drug reactions: an overview of special considerations in the management of the elderly patient. Rochon PAAnderson GMTu JV et al.
Age- and gender-related use of low-dose drug therapy: the need to manufacture low-dose therapy and evaluate the minimum effective dose. J Am Geriatr Soc. Kaplan NM Guidelines for the treatment of hypertension: an American view: Fifth Joint National Committee.
J Hypertens Suppl. Julius S Current trends in the treatment of hypertension: a mixed picture. Frohlich ED Continuing advances in hypertension: the Joint National Committee's fifth report.
Am J Med Sci. Ray WAGriffin MRAvorn J Evaluating drugs after their approval for clinical use. Siegel DLopez J Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Lenfant C JNC guidelines: is the message getting through?
See More About Clinical Pharmacy and Pharmacology Hypertension Adverse Drug Events. Select Your Interests Select Your Interests Customize your JAMA Network experience by selecting one or more topics from the list below.
Save Preferences. Privacy Policy Terms of Use. This Issue. Citations View Metrics. X Facebook More LinkedIn. Cite This Citation Cohen JS. Original Investigation. March 26, Jay S. Cohen, MD. The results of the present study showed that hypertensive patients who used different types of antihypertensive medications did not show any significant difference in survival, hospital stay, ICU admission, disease severity, and invasive medical ventilation as an important clinical outcome in other normotensive patients with COVID Based on the results, prescribing antihypertensive medication to all patients with COVID to improve the clinical profile of COVID may not lead to desired outcomes.
However, conflicting results reported in different studies with different sample sizes and also different study designs warrant the need for future well-designed studies to identify the role of antihypertensive medications for normotensive patients with COVID or all patients with COVID Antihypertensive medications that control the ACE or the receptor blocker of this enzyme may prevent severe COVID in patients with high blood pressure.
Hypertensive patients with different types of antihypertensive medications was similar in COVID severity like other normotensive patients.
Prescribing antihypertensive medication to all patients with COVID to improve the clinical profile of COVID may not lead to desired outcomes.
Meo SA, Al-Khlaiwi T, Usmani AM, Meo AS, Klonoff DC, Hoang TD. Biological and epidemiological trends in the prevalence and mortality due to outbreaks of novel coronavirus COVID J King Saud Univ-Sci.
Article PubMed PubMed Central Google Scholar. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with novel coronavirus in Wuhan, China.
Article CAS PubMed PubMed Central Google Scholar. Zhang Y, Sha T, Wu F, Hu H, Chen Z, Li H, et al. Hypertension in patients hospitalized with COVID in Wuhan, China: a single-center retrospective observational study. Int Heart J.
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy.
Roncon L, Zuin M, Zuliani G, Rigatelli G. Patients with arterial hypertension and COVID are at higher risk of ICU admission.
Br J Anaesth. Article CAS PubMed Google Scholar. Wevers BA, Hoek LVD. Renin—angiotensin system in human coronavirus pathogenesis. Future Virol. Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: the first decade. Int J Hypertens.
Abdul-Hafez A, Mohamed T, Omar H, Shemis M, Uhal BD. The renin angiotensin system in liver and lung: impact and therapeutic potential in organ fibrosis. J Lung Pulmonary Respiratory Res. Chappell MC, Al Zayadneh EM Angiotensin- and the regulation of anti-fibrotic signaling pathways. Journal of cell signaling.
Yang P, Gu H, Zhao Z, Wang W, Cao B, Lai C, et al. Angiotensin-converting enzyme 2 ACE2 mediates influenza H7N9 virus-induced acute lung injury. Sci Rep. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT findings in coronavirus disease COVID : relationship to duration of infection.
Zeinalian M, Salari-Jazi A, Jannesari A, Khanahmad H. A potential protective role of losartan against coronavirus-induced lung damage. Infect Control Hosp Epidemiol. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Retraction: cardiovascular disease, drug therapy, and mortality in Covid N Engl J Med.
Mass Medical Soc; Fact sheet on Hypertension [Internet]. World Health Organization. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of patients infected with SARS-CoV-2 in Wuhan, China.
Yanai H. A significance of high prevalence of diabetes and hypertension in severe COVID patients. J Clin Med Res. Zhou X, Zhu J, Xu T. Clinical characteristics of coronavirus disease COVID patients with hypertension on renin-angiotensin system inhibitors.
Clin Exp Hypertens. Huang S, Wang J, Liu F, Liu J, Cao G, Yang C, et al. COVID patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertension Res. Article CAS Google Scholar. Okay G, Durdu B, Akkoyunlu Y, BÖLÜKÇÜ S, KaÇMaz A, Sümbül B, et al. Evaluation of clinical features and prognosis in COVID patients with hypertension: a single-center Retrospective Observational Study.
Google Scholar. Xie J, Covassin N, Fan Z, Singh P, Gao W, Li G, et al. Association between hypoxemia and mortality in patients with COVID Mayo Clin Proc. Vold ML, Aasebø U, Melbye H. Low FEV1, smoking history, and obesity are factors associated with oxygen saturation decrease in an adult population cohort.
Int J Chron Obstruct Pulmon Dis. Sharma G, Goodwin J. Effect of aging on respiratory system physiology and immunology. Clin Inter Aging. Cheung BMY, Ong K-L, Tso AWK, Cherny SS, Sham P-C, Lam T-H, et al.
Gamma-glutamyl transferase level predicts the development of hypertension in Hong Kong Chinese. Clin Chim Acta.
Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. Bautista LE, Vera LM, Arenas IA, Gamarra G.
Independent association between inflammatory markers C-reactive protein, interleukin-6, and TNF-α and essential hypertension. J Hum Hypertension.
Xiang D, Ren X, Chen Q, Yu H, Li X, Liu D. Sardu C, Maggi P, Messina V, Iuliano P, Sardu A, Iovinella V, et al. Data From Centers of Southern Italy.
J Am Heart Assoc. Ibrahim IA, Al-Joudi FS, Sulaiman RW, Al-Saffar BH. Captopril interferes with some serum biochemical findings. Afr J Biochem Res. CAS Google Scholar. Erhabor O, Shehu A, Erhabor T, Adias TC, Iwueke IP. Some full blood count parameters among hypertensive patients attending specialist Hospital, Sokoto, Nigeria.
Open J Blood Dis. Kato J, Kitamura K, Eto T. Plasma adrenomedullin level and development of hypertension. Hidru TH, Yang X, Xia Y, Ma L, Li H-H. The relationship between plasma markers and essential hypertension in middle-aged and elderly Chinese population: a community based cross-sectional study.
Velazquez S, Madurga R, Castellano JM, Rodriguez-Pascual J, Obregon SRDAD, Jimeno S, et al. Hemogram-derived ratios as prognostic markers of ICU admission in COVID BMC Emerg Med. Article Google Scholar. Enawgaw B, Adane N, Terefe B, Asrie F, Melku M. A comparative cross-sectional study of some hematological parameters of hypertensive and normotensive individuals at the university of Gondar hospital, Northwest Ethiopia.
BMC Hematol. Turan O, Mirici A, Duru Akçalı S, Turan PA, Batum Ö, Şengül A, et al. Int J Clin Pract. Acar E, Demir A, Yıldırım B, Kaya MG, Gökçek K. The role of hemogram parameters and C-reactive protein in predicting mortality in COVID infection.
Tsounis D, Bouras G, Giannopoulos G, Papadimitriou C, Alexopoulos D, Deftereos S. Inflammation markers in essential hypertension. Medicinal Chem. Jayedi A, Rahimi K, Bautista LE, Nazarzadeh M, Zargar MS, Shab-Bidar S. Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies.
Atsma F, Veldhuizen I, de Kort W, van Kraaij M, Pasker-de Jong P, Deinum J. Hemoglobin Level Is Positively Associated with blood pressure in a large cohort of healthy individuals. Xuan Y, Zuo J, Zheng S, Ji J, Qian Y. Association of hemoglobin and blood pressure in a Chinese Community-Dwelling population.
Yakup K, Slam D, Jia HAN, Patar A, Uwat Y. Research on the Association about Serum Iron and Hemoglobin with Essential Hypertension in Kazak People. Guangdong Trace Elements Science. Sica DA, Mannino R. Antihypertensive Medications and Anemia. J Clin Hypertension. Nishida Y, Takahashi Y, Nakayama T, Asai S.
Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes. Cardiovascular Diabetol. Ajmal A, Gessert CE, Johnson BP, Renier CM, Palcher JA.
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels. BMC Res Notes. Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, et al. Association of hypertension and antihypertensive treatment with COVID mortality: a retrospective observational study.
Eur Heart J. López-Otero D, López-Pais J, Cacho-Antonio CE, Antúnez-Muiños PJ, González-Ferrero T, Pérez-Poza M, et al. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID in a western population.
CARDIOVID registry. Rev Española de Cardiolía Engl Ed. Negreira-Caamaño M, Piqueras-Flores J, Martínez-DelRio J, Nieto-Sandoval-Martin-DeLaSierra P, Aguila-Gordo D, Mateo-Gomez C, et al. Impact of treatment with Renin—Angiotensin System inhibitors on clinical outcomes in hypertensive patients hospitalized with COVID Genet B, Vidal J-S, Cohen A, Boully C, Beunardeau M, Marine Harlé L, et al.
COVID In-Hospital mortality and use of renin-angiotensin system blockers in geriatrics patients. J Am Med Dir Assoc. Hypertension: WHO; [updated 25 August ; cited Nov 10]. More than million people with untreated hypertension: WHO; [updated 25 August ; cited Nov 10]. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al.
Worldwide trends in hypertension prevalence and progress in treatment and control from to a pooled analysis of population-representative studies with million participants. Oori MJ, Mohammadi F, Norozi K, Fallahi-Khoshknab M, Ebadi A, Gheshlagh RG. Prevalence of HTN in Iran: meta-analysis of published studies in — Curr Hypertension Rev.
Katibeh M, Moghaddam A, Yaseri M, Neupane D, Kallestrup P, Ahmadieh H. Hypertension and associated factors in the Islamic Republic of Iran: a population-based study. Eastern Mediterranean Health J.
Najafipour H, Nasri HR, Rostamzadeh F, Amirzadeh R, Shadkam M, Mirzazadeh A. J Hum Hypertens. Download references. We would like to appreciate all nurses and physicians who worked in the COVID special ward of Afzalipour Hospital in Kerman.
Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran. Department of Traditional Medicine, School of Traditional Medicine, Kerman University of Medical Sciences, Kerman, Iran.
You can also search for this author in PubMed Google Scholar. and F. have made substantial contributions to the development of this manuscript and data interpretation. and S. were involved in data analysis and its interpretation, and have also made substantial contributions to the development of the manuscript.
All authors have been involved in revising and providing a critical review of the manuscript and have provided their approval to submit the manuscript. Correspondence to Faranak Salajegheh. Reprints and permissions.
Nakhaie, S. et al. The effects of antihypertensive medications on severity and outcomes of hypertensive patients with COVID J Hum Hypertens 37 , — Download citation. Received : 30 June Revised : 19 February Accepted : 14 June Published : 05 July Issue Date : July Anyone you share the following link with will be able to read this content:.
Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Naunyn-Schmiedeberg's Archives of Pharmacology Skip to main content Thank you for visiting nature.
nature journal of human hypertension articles article. Download PDF. Subjects Prognosis Renovascular hypertension. Abstract In Covid pandemic, specific comorbidities are associated with the increased risk of worse outcomes and increased severity of lung injury and mortality.
Acute kidney injury Article 15 July Management of hypertensive crisis: British and Irish Hypertension Society Position document Article Open access 22 November Pulmonary hypertension Article 04 January
Apple cider vinegar for bloating Disclosures. Please Anti-hypertensive effects the Disclaimer Anti-hypertensive effects the end of this page. Anti-hjpertensive several decades, the Anti-hypertensive effects eg, number and doses efects antihypertensive drug therapy has been recognized Anti-hypertendive being Anti-hypertensiv important for Anti-hyoertensive cardiovascular disease Anti-hypertensiv the choice of which specific drug to use initially. In addition, although selected antihypertensive drug classes are more beneficial than others in patients with certain comorbidities, the clinical benefit of antihypertensive drug therapy in the majority of patients is linked to the magnitude of blood pressure lowering, rather than the choice of drug. The approach to antihypertensive drug selection, titration, and combination is discussed in this topic. Other content related to hypertension is presented elsewhere:.
es Wird sich das gute Ergebnis ergeben
Diese einfach unvergleichliche Mitteilung